# ParcelBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/parcelbio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.parcelbio.com
- Total disclosed funding: $13M
- Latest round: Seed (Feb 6, 2026)
- Investors on record: 7

## About

Based in California, US, and founded in 2024, Parcel Biosciences Inc d.b.a., ParcelBio provides RNA-based drugs. The company was co-founded by David Weinberg (CEO), and Chris Carlson. In May 2026, ParcelBio raised USD 13 million in seed funding led by new investor Breyer Capital, with participation from other new investors General Catalyst Partners, Y Combinator, Metaplanet Holdings, ZAKA, and SurgePoint Capital. Other unspecified investors also participated in the round.

The company offers programmable technology that delivers mRNA to various cell types throughout the body. The firm Stabilized Targeted mRNA Platform (STAmP) offers a nanoparticle-free solution. It stabilizes mRNA and incorporates an interchangeable lock-and-key-like targeting mechanism, enabling fully customizable mRNA medicines tailored to specific therapeutic needs. The company will use the May 2026 funding to support platform development and advance its mRNA therapeutic pipeline.

## Funding rounds

- Seed, Feb 6, 2026, $13M — General Catalyst Partners, Y Combinator, Breyer Capital, Metaplanet Holdings, ZAKA, SurgePoint Capital
- Seed, Mar 20, 2024 — Pioneer Fund

## Investors

- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Seed
- Metaplanet Holdings (https://capitalatlas.ai/funds/metaplanet-holdings) — Seed
- ZAKA (https://capitalatlas.ai/funds/zaka) — Seed
- SurgePoint Capital (https://capitalatlas.ai/funds/surgepoint-capital) — Seed